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Calcium citrate, a nonaluminum-containing phosphate-binding agent
for treatment of CRF. Calcium citrate was evaluated as a dietary
phosphate binder in 81 patients with end—stage renal disease. These
patients were grouped as follows: Group 1, 43 patients who were
treated with calcium citrate; and Group 2 (the control group), 38
patients who were treated with aluminum-containing compounds.
Blood chemistries were measured monthly and medications adjusted to
maintain the following levels: serum calcium, >9 mg/dl; serum phos-
phorus, <5.5 mg/dl; and total CO2 content, >22 mmol/liter. At the end
of the treatment period, the following serum values were obtained in
Groups 1 and 2, respectively: calcium, 9.6 1.2 mg/dl (mean SD)
versus 8.9 0.8 mg/dl (P < 0.001); phosphorus 5.5 1.9 mgldl versus
7.0 2.3 mg/dl (P < 0.005); and calcium-phosphate product, 52 18
versus 61 21 (P < 0.05). Differences in alkaline phosphatase, total
CO2 content, and C-terminal parathyroid hormone (C-PTH) values
were not statistically significant between the two groups. Fifteen
patients in Group 1 were then switched to aluminum-containing com-
pounds and chemistries were compared one month later. During
calcium citrate therapy, serum calcium was significantly higher, while
C-PTH and serum alkaline phosphatase were significantly reduced. No
difference was noted in serum phosphorous and total CO2 content. A
questionnaire completed by 17 patients in Group 1 documented excel-
lent patient tolerance to calcium citrate. Hypercalcemia (>10.5 mgldl)
was the only significant complication, but only one patient became
symptomatic. We conclude that, as a phosphate binder, calcium citrate
is at least as effective as aluminum-containing compounds.
Aluminum-containing compounds have been principal agents
for binding dietary phosphorus and controlling secondary hy-
perparathyroidism in patients with chronic renal failure. How-
ever, with the current practice of removing aluminum from
dialysate water, aluminum-containing phosphate binders are an
important source of aluminum exposure in these patients [1—3].
In cases of renal failure, the kidney is not able to excrete the
excess aluminum, and tissue accumulation occurs [1—3]. Con-
cern over the association of excess aluminum in brain and bone
with the development of encephalopathy [51,osteomalacia [1],
and other, less severe degrees of bone disease [4] has generated
interest in evaluating alternative phosphate-binding agents that
do not contain aluminum. Calcium carbonate has been shown to
be effective in controlling the hyperphosphatemia and hypo-
calcemia of patients with chronic renal failure 16—8]. Balance
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Zobitz and Pak, showed that during administration of calcium
citrate, fecal phosphorus excretion increased, urine phosphorus
excretion fell, and calcium balance became more positive [9,
10]. These observations suggest that calcium citrate is capable
both of binding dietary phosphorus and providing supplemental
calcium. Thus, theoretically, calcium citrate should be able to
control both hyperphosphatemia and hypocalcemia. Addition-
ally, by providing alkali in the form of citrate, calcium citrate
may be efficacious in controlling the metabolic acidosis associ-
ated with renal failure. We, therefore, compared calcium citrate
and aluminum-containing antacids as therapeutic agents in
patients with chronic renal failure.
Methods
This study was approved by the Clinical Investigation Com-
mittee at Brooke Army Medical Center, and details and risks
were explained to all patients before they consented to enter the
study. Patient entrance criteria mandated that at least one of the
following laboratory values be persistently abnormal during the
six months immediately prior to the study: serum calcium, <9.0
mg/dl; serum phosphorus, >5.5 mgldl; or serum total CO2
content, <22 mmol/liter. Eighty-one patients from Brooke
Army Medical Center and a private dialysis unit in San Anto-
nio, Texas, agreed to participate. These patients were grouped
as follows: Group 1, 43 patients who were treated with calcium
citrate as a phosphate-binding agent; and Group 2 (the control
group), 38 patients who were treated with aluminum-containing
compounds as a phosphate-binding agent. All but two patients
had been treated with maintenance dialysis for at least one year
before beginning the study. These two patients, both of whom
were enrolled in Group 1, had severe chronic renal failure and
were treated initially with diet. Both required the initiation of
maintenance dialysis during the course of this study. All pa-
tients were instructed on a diet containing 35 kcal/kglday, 1 to
1.2 g of protein per kilogram, and 800 to 1000 mg of phosphorus
daily. Dialysis treatments were performed thrice weekly with
hollow fiber dialyzers, and dialysate water was treated with
reverse osmosis and deionization to remove aluminum. Two
patients, both of whom were enrolled in Group 1, were treated
with continuous cycling peritoneal dialysis. Composition of
dialysate was 3 or 3.5 mEq/liter of calcium, 36 mmollliter of
acetate, and 0.5 to 1.5 mmollliter of magnesium.
All aluminum-containing compounds, alkalinizing agents,
and calcium supplements were discontinued in Group 1 patients
upon entry into the study. Each calcium citrate tablet (Mission
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Table 1. Pre-study comparison of treatment groups of patients with
renal disease
Calcium Aluminum
citrate antacids
Group 1; Group 2;N=43 N=38
Age years 55.7 16.4 61 15.6
Sex
men 24 21
women 19 17
Renal failure etiology
Diabetes mellitus 10 20
Hypertension 10 9
Glomerulonephritis 12 7
Polycystic kidney 5 0
disease
Unknown cause 6 2
Number receiving 6 6
vitamin-D therapy
Number receiving alkali 11 2
Pharmacal Company, San Antonio, Texas, USA) contains 200
mg of elemental calcium and 10 mEq of citrate. Patients in
Group 2 were treated with aluminum-containing compounds as
their phosphate binder. All patients were instructed to ingest
phosphate binders with meals. Seventeen of the 38 patients in
Group 2 required supplemental calcium, administered as cal-
cium carbonate in a dose of 1.7 0.75 g of elemental calcium
per day. Group I and 2 patients treated with vitamin D were
maintained on this therapy. Two Group 2 patients treated with
sodium citrate at the start of the study remained on the drug.
Additional alkali was not added to the treatment regimen of any
other Group 2 patient during the course of the study.
Pre-dialysis blood chemistries (midweek) were measured
monthly. Medications were adjusted in an attempt to maintain
the serum calcium level at >9.0 mgldl, serum phosphorus at
<5.5 mgldl, and total CO2 content at >22 mmol/liter. The
following laboratory tests were monitored: serum calcium,
serum phosphorus, alkaline phosphatase, total carbon dioxide
content, and calcium-phosphate product. C-terminal parathy-
roid hormone (C-VFH) levels (Nichols Institute Assay) were
determined in some patients in Groups 1 and 2. These were
accomplished at baseline (at the beginning of the study) and at
the completion of the study. Baseline chemistries represented
the mean of the monthly values obtained during the six months
before the patients entered the study. The chemistries obtained
at baseline and at the end of the study were compared between
Groups 1 and 2. When this portion of the study was completed,
15 patients were crossed over from treatment with calcium
citrate to treatment with aluminum-containing compounds, and
serum chemistries were monitored every two weeks. The last
set of chemistries obtained during calcium citrate therapy was
compared with the values obtained after one month of alumi-
num treatment. Blood chemistries were performed on a
Technicon SMAC Biochemical Analyzer (Technicon Corpora-
tion, Tarrytown, New York, USA).
All data are expressed as mean SD. Patients in Groups 1
and 2 were compared by a two-tailed Student's t-test. A
Student's t-test also was accomplished to assess changes in
alkaline phosphatase and C-PTH utilizing paired data for the
Table 2. Biochemical values
Aluminum
Calcium citrate antacids
Group 1; Group 2;N=43 N=38
Baseline
Serum calcium mg/d! 9.0 1.oa NS 8.8 1.3
Serum phosphorus mg/dl 6.3 1.9 NS 6.0 2.1
Alkaline phosphatase U/liter 122 61 NS 109 48
Total CO2 mmol/iiter 18.1 2.6 NS 18 3.2
Calcium phosphate product
C-PTH pg/rn/b
55 14
10,245 10,003N=30
NS
NS
53 19
7882 9738
N=lO
End of treatment
Months of treatment 9.1 3.1 NS 10.2 2.3
Serum calcium mg/dl 9.6 1.2 <0.001 8,9 0.8
Serum phosphorus mg/di 5.5 1.9 <0.005 7.0 2.3
Alkaline phosphatase U/liter 110 64 NS 109 46
Total CO2 mmol/liter 19.5 3,5 NS 18.4 3.3
Calcium phosphate product 52 18 <0.05 61 21
C-PTH pg/mi 7260 8223
N=28
NS 7708 8056
N=13
a Mean SD
b Nichols Institute Assay, upper limit of normal < 310 pg/ml
two groups. Results from the crossover study were compared
by a paired I-test and by a Mann-Whitney rank and sum test.
Questionnaires were distributed to 17 patients in Group 1
who had received treatment with three different phosphate-
binding agents over the preceding two years: calcium carbon-
ate, calcium citrate, and aluminum-containing compounds. The
intent was to obtain information concerning patient preference
and complications with each of these agents.
Results
The patients in Groups 1 and 2 were comparable with respect
to age and sex (Table 1). Diabetes mellitus was more prevalent
in the patients in Group 2, and polycystic kidney disease was
present only in patients enrolled in Group 1; otherwise, the
cause of the underlying renal disease was similar. The same
number of patients in each group received oral vitamin-D
therapy (1,25 dihydroxy-cholecalciferol). The baseline bio-
chemical values shown in Table 2 confirm that there was no
difference in values between Groups 1 and 2. Patients in Groups
1 and 2 completed a mean of 9.1 and 10.2 months of therapy,
respectively. At the end of the treatment period, the patients in
Group 1 had a significantly higher serum calcium and a signif-
icantly lower serum phosphorus and calcium-phosphate prod-
uct (Table 2) than did the patients in Group 2. Total carbon
dioxide content, alkaline phosphatase, and C-PTH levels were
not different at the end of the study (Table 2). Differences for
alkaline phosphatase and C-PTH also were not found when
comparing changes in values utilizing paired data for the two
treatment groups. The mean SD dose of elemental calcium
utilized in Group 1 patients was 1.79 0.93 g daily, and the
dose of aluminum utilized in patients in Group 2 was 2.76 1.9
g per day.
In the group of 15 patients crossed over from calcium citrate
to aluminum therapy, there was evidence of better control of
hyperparathyroidism during calcium-citrate therapy. Serum
calcium was significantly increased, and C-PTH and alkaline
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Table 3. Biochemical values of 15 patients switched from calcium
citrate to aluminum
Calcium
citrate
Aluminum
antacids p1' pc
Serum calcium mg/dl 10.2 0.9 9.6 0.8 0.037 0.035
Serum phosphorus mg/di 4.9 1.0 5.2 1.2 0.45 0.500
Alkaline phosphatase 78 39 92 43 0.0000 0.001
U/liter
Total CO2 mmol/liter 17.8 5.3 18.1 2.7 0.13 0.103
Calcium phosphate product 50 12 50 13 0.89 0.932
C-PTH pg/rn! 8613 9115 9113 9112 0.038 0.025
a Mean SD
b Paired Student's t-test
C Mann-Whitney rank and sum test
phosphatase were significantly reduced (Table 3). Serum phos-
phorus, total carbon dioxide content, and calcium-phosphate
product were unchanged. These findings were the same when
the data was compared with a paired Student's t-test and with a
Mann-Whitney rank and sum test.
In six patients enrolled in Group 1, serum total CO2 content
remained low, and sodium citrate, therefore, was added to their
regime. In another three patients, control of serum phosphorus
was inadequate with calcium citrate treatment alone, and alu-
minum-containing compounds were added.
Patient preference as assessed by questionnaire disclosed
that six favored calcium citrate; three, calcium carbonate; and
three, aluminum antacids. Three patients thought that all three
agents were equally good, and one preferred calcium citrate and
calcium carbonate equally. Forty-one percent of 17 responders
stated that they did not require laxatives during aluminum
administration. Of the nine patients who did require laxatives
during aluminum therapy, only two were able to discontinue
them upon conversion to calcium citrate. Hypercalcemia (se-
rum calcium >10.5 mgldl) was the major complication observed
in patients treated with calcium citrate. This occurred in 39% of
our 43 treated patients during 17.8% of 387 patient months of
treatment. Serum calcium >11.0 mgldl occurred in 9.3% of 387
patient-months of treatment. One patient developed sympto-
matic hypercalcemia, as manifested by confusion. In the re-
mainder, the hypercalcemia was asymptomatic.
Discussion
Aluminum excess has been implicated in a number of disor-
ders in patients with renal insufficiency, including osteomalacia,
other less severe degrees of osteodystrophy, encephalopathy,
and microcytic anemia [1, 4, 111. The predominant sources of
aluminum exposure are untreated dialysate water with a high
aluminum content and aluminum-containing phosphate binders
[1, 2, 121. Recognition of aluminum-associated syndromes has
resulted in aluminum removal from dialysate, and a notable
reduction in the incidence of these syndromes [12, 13]. How-
ever, aluminum-containing phosphate binders still constitute an
important source of exposure [1, 2]. The role of aluminum in the
development of uremic bone disease has been reviewed [14,
15], and it seems prudent to further reduce aluminum exposure
by formulating alternative phosphate-binding agents.
Calcium carbonate has been shown to be effective in control-
ling hyperphosphatemia and secondary hyperparathyroidism in
patients with chronic renal failure [6—8]. Based on our study,
the ability of calcium citrate to provide control of serum
phosphorus and to increase serum calcium appears to be
similar. Several potential difficulties in design, however, make
the long-term implications of our study less than precise.
Enrollee phosphorus intake was not quantitated, and the cross-
over study lasted for only a short period of time. Thus, to
establish the relative efficacy of calcium citrate and calcium
carbonate, a direct comparison study between the two drugs is
needed. Like calcium carbonate, calcium citrate did not provide
sufficient alkali to increase the serum total CO2 content (Tables
2 and 3). Calcium citrate seemed to provide better control of
secondary hyperparathyroidism in our crossover study than did
aluminum-containing products (Table 3). However, due to the
relatively short period of time that patients were treated with
either drug, longer follow-up will be required to assure that the
differences observed are sustained.
It is likely that the higher serum calcium in Group 1 patients
(Table 2) was due to the provision of supplemental calcium.
However, there were more diabetics enrolled in Group 2 (Table
1). Vincenti et al reported that diabetics with end-stage renal
disease have significantly lower levels of serum calcium than
nondiabetics [16]. This may have been a contributing factor in
our study.
A word of caution is in order with regard to treating patients
with the combination of aluminum-containing compounds and
calcium citrate. Rats treated with aluminum citrate, or a normal
diet and citric acid, were found to have significantly higher
levels of brain and bone aluminum content than animals receiv-
ing aluminum hydroxides alone [17]. Presumably citrate and
citric acid increased intestinal aluminum absorption [17]. The
same authors reached a similar conclusion in their study of the
effects of dietary citric acid on the absorption of aluminum in
antacids in 10 healthy males [18]. In addition, it has been found
that the combination of citric acid and aluminum (or citric acid
with other metals such as iron and chromium) impairs calcium
phosphate precipitation in a solution of hydroxyapetite, and
impedes calcium uptake onto tendon slices in vitro [19, 20]. On
the basis of these observations, it has been suggested that
aluminum citrate may form a complex that inhibits bone
growth, and thus may exacerbate aluminum-associated osteo-
malacia [21]. Although this remains a theoretical possibility,
there is no clinical data to substantiate this claim. We did not
observe symptomatic bone disease during calcium citrate ther-
apy; however, we did not perform bone biopsies in our patients
to assess changes in bone mineralization. Additionally, we
chose not to monitor serum aluminum levels as has been done
in other studies [6—8]. Aluminum-containing compounds and
sodium citrate in combination with citric acid (such as Bicitra'),
are used clinically in patients with renal failure. Recently, Bakir
and colleagues reported an acute fatal encephalopathy associ-
ated with hyperaluminemia in four patients with advanced
chronic renal failure treated with oral aluminum hydroxide and
a buffer of citric acid and sodium citrate [22]. Although they did
not prove that aluminum caused the encephalopathy, their data
is suggestive. Thus, it is important that additional studies be
conducted to determine whether citrate has a harmful effect on
increasing aluminum absorption or altering bone mineraliza-
tion. In addition, it is important that careful balance studies be
performed in patients receiving calcium citrate to better under-
stand the effect of this agent on overall mineral metabolism and
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side effects such as soft tissue calcification. Until a full under-
standing of possible interactions between calcium citrate and
aluminum-containing compounds is obtained, they probably
should not be used simultaneously.
The major complication that occurred with calcium citrate
administration was hypercalcemia. The incidence of hypercal-
cemia in the current study is similar to that observed in studies
utilizing calcium carbonate [23]. Notwithstanding, the bioavail-
ability of calcium in calcium citrate may be better than in
calcium carbonate [24]. One patient developed symptomatic
hypercalcemia. This reinforces the need for careful patient
follow-up whenever calcium-containing medications are uti-
lized in the end-stage renal disease population. A low calcium
dialysate has been shown to significantly diminish the incidence
of hypercalcemia associated with calcium carbonate treatment
[25]. A similar study is needed with calcium citrate.
Many patients who experienced constipation when treated
with aluminum-containing compounds also experienced this
with calcium citrate. The constipation might have been due to
something other than the aluminum, or it may be that the
calcium citrate is constipating. Patient preference was assessed
in patients who had been treated with three types of phosphate-
binding agents over the preceding two years. Preference was
mixed, and there was no overwhelming consensus that either
calcium citrate, calcium carbonate, or aluminum was best.
Other than providing initial dietary instruction, we did not
monitor patient phosphorus intake during the study. This may
have been responsible for the decreased serum phosphorus in
our patients in Group 1 (Table 2). However, in the 15 patients
crossed-over from calcium citrate treatment to treatment with
aluminum, the serum phosphorus was controlled equally well
with calcium citrate and aluminum-containing compounds (Ta-
ble 3). In contrast to aluminum, calcium-containing phosphate
binders may result in a decrease in serum phosphorus due both
to binding of dietary phosphorus and to precipitation of calcium
phosphate into soft tissues.
In conclusion, treatment with calcium citrate controlled
hyperphosphatemia at least as well as treatment with alumi-
num-containing compounds. Ramirez et al have shown that
dietary phosphorus absorption in dialysis patients is reduced to
a comparable degree with calcium carbonate treatment and
aluminum hydroxide treatment [26]. Our observation that se-
rum phosphorus was similarly controlled by treatment with
calcium citrate and aluminum-containing compounds suggests
that calcium citrate and calcium carbonate may be equally
efficacious. The choice of a nonaluminum-containing agent to
reduce aluminum exposure might presumably, over a long
period, diminish tissue accumulation. This is offset to a degree
by the development, in some patients, of hypercalcemia. Al-
though all but one of our hypercalcemic patients were asymp-
tomatic, the long-term effect of mild hypercalcemia requires
further study. Additionally, the effect of the various types of
phosphate binders on histologic bone changes in patients with
renal insufficiency should be evaluated to determine if one agent
is superior to another.
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